GILD vs GSK

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 27, 2026

GILD

42.5
AI Score
VS
GSK Wins

GSK

46.9
AI Score

Investment Advisor Scores

GILD

43score
Recommendation
HOLD

GSK

47score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric GILD GSK Winner
Forward P/E 15.5521 9.7656 GSK
PEG Ratio 2.2696 6.1023 GILD
Revenue Growth 10.2% 5.3% GILD
Earnings Growth 54.8% -69.5% GILD
Tradestie Score 42.5/100 46.9/100 GSK
Profit Margin -10.6% 14.5% GSK
Beta 1.00 1.00 Tie
AI Recommendation HOLD HOLD Tie

Relative Price Performance (Last 90 Days)

GILD 1M: +2.3% · 3M: +20.5% GSK 1M: -1.1% · 3M: -5.9%

Current Technical Phase

GILD

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (5.8% over 20 days), RSI 62

RSI (14): 62.2 · Price: $152.21

GSK

Distribution
Trim / tighten stop

Price near a flattening SMA50 (slope -1.8%) with fading momentum, RSI 47

RSI (14): 46.7 · Price: $49.70

Fundamentals Snapshot

Metric GILD GSK
Market Cap — —
Forward P/E 15.4 9.9
Trailing P/E — 15.8
Revenue (TTM) — —
Revenue Growth 0.1% 0.1%
Gross Margin 0.8% 0.7%
Operating Margin 0.3% 0.3%
EPS -2.66 3.11
Dividend Yield 0.02% 0.04%

Frequently Asked Questions

Based on our detailed analysis, GSK is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.